Background: Current clinical criteria for identifying anaphylaxis do not account for unique aspects of infant anaphylaxis presentation and have not been validated in patients younger than 2 years of age. This may contribute to under recognition and is thus an unmet need.
Objective: To demonstrate age-specific signs and symptoms that more accurately identify anaphylaxis in young children and to develop and compare modified criteria for "likely anaphylaxis" against the widely used 2006 National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network (NIAID/FAAN) criteria.
Methods: Retrospective chart review of 337 clinical encounters presenting with suspected allergic or anaphylactic reactions to a pediatric emergency department. Modified criteria for likely anaphylaxis were developed and evaluated against the NIAID/FAAN criteria.
Results: The study population included 33% infants (age < 12 mo), 39% toddlers (age 12 mo to < 36 mo), and 29% children (age ≥ 36 mo). The NIAID/FAAN criteria captured 85% of all patient encounters in the study and the modified criteria captured 98% (P < .001). Compared with NIAID/FAAN criteria, modified criteria had 22.8% improved performance among infants (p < .001) and 10.3% improved performance among toddlers (P = .04).
Conclusions: We developed modified anaphylaxis clinical criteria that incorporated symptoms specific to infants and young children. The modified criteria increased identification of anaphylaxis in infants and potentially toddlers. Future research is needed to validate our findings on a larger cohort.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493081 | PMC |
http://dx.doi.org/10.1016/j.jaip.2024.05.018 | DOI Listing |
Clin J Gastroenterol
January 2025
University of Connecticut, Connecticut, USA.
Marginal ulcers are a common complication following Roux-en-Y bypass surgeries with an approximate incidence of 4.6%. The pathophysiology is complex and risk factors include smoking, nonsteroidal anti-inflammatory drugs (NSAIDs) use, Helicobacter pylori infection, and a larger pouch size.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Mathematics, Birla Institute of Technology and Science Pilani, Pilani Campus, Pilani, Rajasthan, 333031, India.
As India's population grows and urbanization accelerates, energy demand is increasing sharply while conventional sources fall behind. To tackle energy shortages and climate change, India must prioritize renewable energy sources (RES), which offer sustainable solutions. The country is rich in RES, which can enhance fuel mix for electricity generation.
View Article and Find Full Text PDFJ Prosthet Dent
January 2025
Associate Professor, Department of Clinical Science, College of Dentistry, Ajman University, Ajman City, United Arab Emirates.
Statement Of Problem: Different factors affect 3-dimensionally (3D) printed resin products. However, evidence on the effect of the print orientation on resin dental devices is lacking.
Purpose: The purpose of this systematic review and meta-analysis was to assess the impact of print orientation on the properties and accuracy of 3D printed implant surgical guides, occlusal devices, clear orthodontic retainers, and aligners.
J Cancer Surviv
January 2025
School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Purpose: This study aimed to evaluate the prevalence and predictors of frailty and the association between frailty and neurocognitive impairments among Chinese survivors of childhood cancer.
Methods: A total of 185 survivors of childhood cancer were recruited from a long-term follow-up clinic in Hong Kong (response rate: 94.4%; 48.
RMD Open
January 2025
Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Objective: The objective of this study is to evaluate the efficacy and safety of jaktinib hydrochloride tablets (jaktinib), a Janus kinase inhibitor, in patients with active radiographic axial spondyloarthritis (r-axSpA).
Methods: Adults with active r-axSpA who met modified New York criteria and had an inadequate response to non-steroidal anti-inflammatory drugs were randomised 1:1:1 to receive jaktinib 75 mg two times per day, 100 mg two times per day, or placebo. The primary and key secondary endpoints were Assessment of SpondyloArthritis international Society 20 (ASAS 20) and ASAS 40 responses, respectively, at week 16.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!